Travis Steed
Stock Analyst at B of A Securities
(2.92)
# 1,256
Out of 4,667 analysts
79
Total ratings
44.26%
Success rate
9.09%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CBLL CeriBell | Initiates: Buy | $32 | $25.38 | +26.10% | 1 | Nov 5, 2024 | |
| EW Edwards Lifesciences | Downgrades: Neutral | $105 → $75 | $69.80 | +7.46% | 3 | Jul 25, 2024 | |
| SOLV Solventum | Maintains: Neutral | $70 → $60 | $68.40 | -12.27% | 2 | Jun 25, 2024 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $305 → $312 | $221.29 | +40.99% | 6 | May 6, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $32.33 | +39.19% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $32 → $3 | $0.73 | +313.39% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $387.08 | -18.62% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $266.58 | +10.66% | 3 | Aug 24, 2023 | |
| AXGN Axogen | Reiterates: Overweight | $16 | $12.90 | +24.03% | 5 | Aug 22, 2023 | |
| TNDM Tandem Diabetes Care | Downgrades: Underperform | $45 → $33 | $30.15 | +9.45% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $109.27 | +46.43% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $541.82 | -41.86% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $6.20 | +29.03% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $13.61 | +83.69% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 | $115.93 | +20.76% | 4 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $18.24 | +366.01% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $75.24 | +66.14% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $84.20 | +72.21% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $90.49 | -43.64% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $71.78 | +143.81% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $22.93 | +135.50% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $86.45 | -74.55% | 1 | Jul 17, 2017 |
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $25.38
Upside: +26.10%
Edwards Lifesciences
Jul 25, 2024
Downgrades: Neutral
Price Target: $105 → $75
Current: $69.80
Upside: +7.46%
Solventum
Jun 25, 2024
Maintains: Neutral
Price Target: $70 → $60
Current: $68.40
Upside: -12.27%
Becton, Dickinson and Company
May 6, 2024
Maintains: Overweight
Price Target: $305 → $312
Current: $221.29
Upside: +40.99%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $32.33
Upside: +39.19%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $32 → $3
Current: $0.73
Upside: +313.39%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $387.08
Upside: -18.62%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $266.58
Upside: +10.66%
Axogen
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $12.90
Upside: +24.03%
Tandem Diabetes Care
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $30.15
Upside: +9.45%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $109.27
Upside: +46.43%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $541.82
Upside: -41.86%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $6.20
Upside: +29.03%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $13.61
Upside: +83.69%
May 31, 2022
Maintains: Buy
Price Target: $140
Current: $115.93
Upside: +20.76%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $18.24
Upside: +366.01%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $75.24
Upside: +66.14%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $84.20
Upside: +72.21%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $90.49
Upside: -43.64%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $71.78
Upside: +143.81%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $22.93
Upside: +135.50%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $86.45
Upside: -74.55%